Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).

MLA

Boni, C., et al. “Triplets versus Doublets, with or without Cisplatin, in the First-Line Treatment of Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) Patients: A Multicenter Randomised Factorial Trial (FAST).” British Journal of Cancer, vol. 106, no. 4, Feb. 2012, pp. 658–65. EBSCOhost, https://doi.org/10.1038/bjc.2011.606.

APA

Boni, C., Tiseo, M., Boni, L., Baldini, E., Recchia, F., Barone, C., Grossi, F., Germano, D., Matano, E., Marini, G., Labianca, R., Di Costanzo, F., Bagnulo, A., Pennucci, C., Caroti, C., Mencoboni, M., Zanelli, F., Prochilo, T., Cafferata, M. A., & Ardizzoni, A. (2012). Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). British Journal of Cancer, 106(4), 658–665. https://doi.org/10.1038/bjc.2011.606

Chicago

Boni, C, M Tiseo, L Boni, E Baldini, F Recchia, C Barone, F Grossi, et al. 2012. “Triplets versus Doublets, with or without Cisplatin, in the First-Line Treatment of Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) Patients: A Multicenter Randomised Factorial Trial (FAST).” British Journal of Cancer 106 (4): 658–65. doi:10.1038/bjc.2011.606.